Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy
Chahin, N.; Sahagian, G.; Feinberg, M. H.; Stewart, C. A.; Jewell, C. M.; Kurtoglu, M.; Miljkovic, M. D.; Vu, T.; Mozaffar, T.; Howard, J. F.
Show abstract
We report the 12-month follow-up results of a phase 2 clinical of Descartes-08 (NCT04146051), BCMA-directed RNA chimeric antigen receptor T-cell (rCAR-T) therapy for myasthenia gravis (MG) given as an outpatient treatment without lymphodepletion. In the Phase 2a part of the study, all 7 participants who received six weekly infusions of Descartes-08 exhibited clinically meaningful improvement in common MG severity scales (MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15-revised) at Month 3. At Month 9 follow-up, all participants continued to experience marked clinical improvements. Five out of seven participants maintained clinical improvement at Month 12. Of the two participants who experienced loss of clinical effect at Month 12 and were eligible for retreatment, one was retreated and had rapid improvement in clinical scores with minimal symptom expression which was ongoing at Month 6 of follow-up. All three participants with detectable anti-acetylcholine receptor (AChR) antibody levels at baseline experienced autoantibody reductions by Month 6, which deepened further by Month 9, and were maintained at Month 12. These data support continued development of Descartes-08 in myasthenia gravis and other autoantibody-associated autoimmune disorders.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study 89%
- SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab 88%
- Long term follow-up in anti-contactin-1 autoimmune nodopathy 87%
Similar papers in this journal
- Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) 86%
- A Predictive Autoantibody Signature in Multiple Sclerosis 86%
- mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant 86%
Similar papers in this journal
- IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality 90%
- SARS-CoV-2 mRNA vaccination fails to elicit humoral and cellular immune responses in multiple sclerosis patients receiving fingolimod 88%
- The effect of GLP-1RA exenatide on Idiopathic Intracranial Hypertension: Randomised Clinical Trial 85%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.